1. In Vivo
  2. >>Growth

The Biopharma A List: Taking The Pulse of Newco Creation In 2024

 
• By Amanda Micklus

The landscape for overall private biotech financing in 2024 featured investors who were interested in funding new developments – if Big Pharma was willing to pay up eventually in partnerships and M&A – but also reluctance as the industry faced macroeconomic and regulatory uncertainties.

(Shutterstock)

A key indicator of the strength of the biopharma industry is the health of new company creation. By reviewing Series A financing announced in 2024 as a proxy, In Vivo once again takes measurement of start-up activity and investor appetite for new and exciting science.

First-time financing by start-ups typically represents a strong proportion of overall venture capital (VC) funding. Since 2017, that percentage has hovered around a third, and in 2024, the Series A class continued that trend, accounting for 34% of all VC financing (see Exhibit 1)

More from Growth

More from In Vivo

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By Jo Shorthouse

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

Califf In Conversation: “Decimated” FDA Teams Endanger Biologics Progress

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.